ICAM-2 Limits Metastasis in Neuroblastoma
Author Information
Author(s): Yoon Karina Jin, Phelps Doris A., Bush Rebecca A., Remack Joanna S., Billups Catherine A., Khoury Joseph D.
Primary Institution: St. Jude Children's Research Hospital
Hypothesis
ICAM-2 expression in neuroblastoma cells affects their motility and metastatic potential.
Conclusion
ICAM-2 expression in neuroblastoma cells is associated with reduced cell motility and a nonmetastatic phenotype.
Supporting Evidence
- ICAM-2 expression was found in primary neuroblastoma tumors associated with limited metastatic disease.
- Neuroblastoma cells expressing ICAM-2 showed reduced motility in scratch assays.
- ICAM-2 expression correlated with favorable clinical outcomes in neuroblastoma patients.
Takeaway
ICAM-2 helps keep cancer cells from moving around and spreading to other parts of the body.
Methodology
The study used co-immunoprecipitation, competitive peptide assays, and in vivo models to assess the role of ICAM-2 in neuroblastoma.
Limitations
The study primarily focused on in vitro and preclinical models, which may not fully replicate human disease.
Participant Demographics
The study included 90 neuroblastoma patient samples from the Children's Oncology Group.
Statistical Information
P-Value
p<0.0003
Statistical Significance
p<0.0003
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website